Phase 1/2, Dose Escalation and Expansion Study of BGB 10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors

Project: Research

Project Details

Project Description

NMA HREC Reference Number: Monash Health HREC ref RES-19-0000-893A
NMA SSA Reference Number: SSA/59209/MonH-2021-247998(v1)
Monash Health Reference: RES-21-0000-043X
Effective start/end date19/03/2118/03/26


  • clinical trial
  • phase 1 and 2 study
  • solid tumours
  • b-cell lymphoma
  • treatment efficacy
  • treatment safety